Circulation:舒张压与心血管事件之间线性和非线性相关性分析

2020-11-30 MedSci原创 MedSci原创

对于DBP,研究人员没有发现DBP与不良CVD结局之间呈非线性J形或U形关系的证据,包括MI。

最新的临床指南支持强化降压(BP)目标。但是,观察数据表明,舒张压(DBP)过度降低可能会增加心肌梗塞(MI)的风险。

近日,血管领域权威杂志Circulation上发表了一篇研究文章,研究人员分析了来自5个队列的47407名参与者(中位年龄为60岁)。首先,为了证实先前的观测分析,研究人员使用传统的统计方法来评估DBP与CVD之间关联的形状。其次,研究人员创建了DBP和SBP的多基因风险评分(PRS),并生成了DBP对CVD影响的线性孟德尔随机(MR)估计。第三,研究人员使用新颖的非线性MR方法,评估了DBP和CVD之间非线性的遗传关系。鉴于两者之间的相关性很强,研究人员对DBP进行全面的MR询问,也需要对SBP进行建模。

研究人员对队列就行传统观察分析表明,DBP与MI之间呈J形关联。相比之下,线性MR分析发现DBP升高对CVD结局(包括MI)会产生不利影响(DBP每增加1 mmHg,MI风险比=1.07,p<0.001)。此外,非线性MR分析没有发现J型关系的证据,而是证实了即使基线DBP值较低的个体,MI风险也随着DBP的降低而持续降低。

由此可见,对于DBP,研究人员没有发现DBP与不良CVD结局之间呈非线性J形或U形关系的证据,包括MI。

原始出处:

Marios Arvanitis,et al.A Linear and Non-Linear Mendelian Randomization Analysis of the Association Between Diastolic Blood Pressure and Cardiovascular Events: The J Curve Revisited.Circulation. 2020.https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.049819

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837890, encodeId=1315183e89068, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Apr 02 17:48:18 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643724, encodeId=e1f51643e242f, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Mar 28 01:48:18 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323118, encodeId=23d913231185c, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Dec 02 12:48:18 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523656, encodeId=c700152365633, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Wed Dec 02 12:48:18 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904002, encodeId=269c90400223, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/28/dc0a622c5c75f55fb8c848c04ece3cdc.jpg, createdBy=916d2333311, createdName=尹乔, createdTime=Tue Dec 01 21:02:51 CST 2020, time=2020-12-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837890, encodeId=1315183e89068, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Apr 02 17:48:18 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643724, encodeId=e1f51643e242f, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Mar 28 01:48:18 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323118, encodeId=23d913231185c, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Dec 02 12:48:18 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523656, encodeId=c700152365633, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Wed Dec 02 12:48:18 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904002, encodeId=269c90400223, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/28/dc0a622c5c75f55fb8c848c04ece3cdc.jpg, createdBy=916d2333311, createdName=尹乔, createdTime=Tue Dec 01 21:02:51 CST 2020, time=2020-12-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837890, encodeId=1315183e89068, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Apr 02 17:48:18 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643724, encodeId=e1f51643e242f, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Mar 28 01:48:18 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323118, encodeId=23d913231185c, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Dec 02 12:48:18 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523656, encodeId=c700152365633, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Wed Dec 02 12:48:18 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904002, encodeId=269c90400223, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/28/dc0a622c5c75f55fb8c848c04ece3cdc.jpg, createdBy=916d2333311, createdName=尹乔, createdTime=Tue Dec 01 21:02:51 CST 2020, time=2020-12-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837890, encodeId=1315183e89068, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Apr 02 17:48:18 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643724, encodeId=e1f51643e242f, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Mar 28 01:48:18 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323118, encodeId=23d913231185c, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Dec 02 12:48:18 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523656, encodeId=c700152365633, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Wed Dec 02 12:48:18 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904002, encodeId=269c90400223, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/28/dc0a622c5c75f55fb8c848c04ece3cdc.jpg, createdBy=916d2333311, createdName=尹乔, createdTime=Tue Dec 01 21:02:51 CST 2020, time=2020-12-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837890, encodeId=1315183e89068, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Fri Apr 02 17:48:18 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643724, encodeId=e1f51643e242f, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Sun Mar 28 01:48:18 CST 2021, time=2021-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323118, encodeId=23d913231185c, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Dec 02 12:48:18 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523656, encodeId=c700152365633, content=<a href='/topic/show?id=f6f1e2533e3' target=_blank style='color:#2F92EE;'>#相关性分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72533, encryptionId=f6f1e2533e3, topicName=相关性分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad8f11536374, createdName=anminleiryan, createdTime=Wed Dec 02 12:48:18 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904002, encodeId=269c90400223, content=赚积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/28/dc0a622c5c75f55fb8c848c04ece3cdc.jpg, createdBy=916d2333311, createdName=尹乔, createdTime=Tue Dec 01 21:02:51 CST 2020, time=2020-12-01, status=1, ipAttribution=)]
    2020-12-01 尹乔

    赚积分

    0

相关资讯

JAHA:HIV感染者社区获得性肺炎与心血管事件风险

调整已知的CVD危险因素和CAP严重程度后,PLWH和未感染HIV的患者在CAP住院期间或之后发生CVD事件的风险相似。然而,在多变量校正模型中,HIV感染与CAP住院后30天死亡率增加相关。

促进2019CCEP专家建议落地, 强调联合治疗,推动超高危患者风险管理改善

我国ASCVD患者血脂管理现状很不乐观。2016年发表的DYSIS-China研究亚组分析显示,二级预防患者LDL-C达标率为33.09%,极高危患者则低于30%。

Diabetes Care:老年糖尿病患者严重低血糖与心脏结构和功能以及心血管事件风险的关系

严重低血糖病史与心脏功能改变有关,并且是老年人未来心血管风险的重要标志。

JAHA:顽固性高血压患者难治性高血压与心血管事件和死亡风险

相比于顽固性非难治性高血压患者,RfHT患者,尤其是根据不受控制的动态血压水平诊断时,发生重大不良CVE和死亡的风险更高。

JAHA:脂蛋白(a)和低密度脂蛋白胆固醇同时升高的心血管事件风险

LDL-C≥135mg/dL和脂蛋白(a)≥100nmol/L的同时升高与较高的心血管疾病绝对风险相关。在LDL-C中度升高的个体中进行脂蛋白(a)测量,可能会识别出具有较高心血管风险的个体。

Circulation:2型糖尿病患者一/二级预防的风险因素控制和心血管事件风险

2型糖尿病(T2D)是一种常见的代谢疾病,可增加多种致命性和非致命性心血管疾病(CVD)的风险。该研究旨在研究T2D的风险因素控制程度与心血管疾风险之间的相关性,同时评估心肾疾病的存在是否会改变这些关